REHOVOT, Israel, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that the Company's CEO, Gil Efron will participate in a fireside chat and 1x1 investor meeting at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8-10, 2025. Details are as follows: H.C. Wainwright 27th Ann ...

Core Insights - ECARX has achieved Automotive SPICE (ASPICE) v4.0 Capability Level 3 (CL3) certification, the highest rating under the ASPICE standard, enhancing its portfolio of certifications necessary for collaboration with leading automakers [1] - The company has established a scalable, compliant software-development backbone through various certifications, including ASPICE v3.1 CL2, CMMI CL3, and ASPICE v3.1 CL3, which strengthens its competitive positioning in the global market [2] - ECARX is committed to developing products in compliance with ISO26262 and ISO21434 standards for functional safety and cybersecurity, further enhancing its competitive edge [2] Company Overview - ECARX is a global automotive technology provider that delivers turnkey solutions for next-generation smart vehicles, including system on a chip (SoC), central computing platforms, and software [4] - Founded in 2017 and listed on Nasdaq in 2022, ECARX has over 1,600 employees across 13 major locations worldwide, including China, the UK, the USA, Singapore, Malaysia, Sweden, and Germany [5] - The company collaborates with notable automakers such as Volkswagen Group, FAW Group, and Dongfeng Peugeot-Citroën, with its products present in over 9.3 million vehicles globally [5] Leadership Perspective - Ziyu Shen, Chairman and CEO of ECARX, emphasized that achieving ASPICE v4.0 CL3 certification reflects the company's focus on R&D capability, quality control, and process maturity, supporting large-scale global mandates like the project with Volkswagen Group [3]

Sales of $115.5 million, Breakeven Net Loss per diluted share Extends Credit Facility to August 2030 CANTON, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Destination XL Group, Inc. (NASDAQ: DXLG), the leading integrated-commerce specialty retailer of Big + Tall men’s clothing and shoes, today reported operating results for the second quarter of fiscal 2025. Second Quarter Financial Highlights Total sales for the second quarter were $115.5 million, down 7.5% from $124.8 million in the second quarter of fiscal 2 ...

Core Insights - Seres Therapeutics, Inc. is a clinical-stage company focused on live biotherapeutics aimed at improving patient outcomes in medically vulnerable populations [2] - The company will present an overview at the H.C. Wainwright Global Investment Conference on September 8, 2025 [1] Company Overview - Seres Therapeutics is known for developing VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024 [2] - The company is currently developing SER-155, which has received Breakthrough Therapy designation for reducing bloodstream infections in adults undergoing allo-HSCT and Fast Track designation for reducing infection risk and graft-versus-host disease in the same patient group [2] - SER-155 has shown a significant reduction in bloodstream infections and related complications compared to placebo in a Phase 1b clinical study [2] Pipeline and Future Plans - The company’s pipeline includes SER-155 and other cultivated live biotherapeutic candidates targeting various disease-relevant pathways [2] - In addition to allo-HSCT, SER-155 and other candidates will be evaluated in other medically vulnerable populations, including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, and patients in intensive care and long-term acute care facilities [2]

Core Viewpoint - U.S. GoldMining Inc. is advancing its exploration efforts at the Whistler Gold-Copper Project in Alaska for the 2025 field season, focusing on developing new drill targets and expanding its resource base [1][4][6]. Exploration Program Details - The 2025 exploration program aims to explore multiple targets across the Whistler Project, with a focus on the Whistler Orbit and Muddy Creek prospect areas [1][4][6]. - The program includes systematic 'scout' drilling over the Whistler – Raintree mineral system, covering an area of approximately 5 x 5 km, and aims to identify fertile porphyry intrusions [6][7]. - The Muddy Creek area has a significant gold-in-soil geochemical footprint of approximately 6 x 4 km, with historic sampling returning values exceeding 1 gram per tonne gold, including peak values of 111.50 g/t Au [6][8]. Political Engagement - U.S. GoldMining hosted U.S. Senator Lisa Murkowski at the Whistler Project on August 21, 2025, highlighting the political interest in responsible resource development in the West Susitna Mineral District [1][5][6]. Resource Estimates - The Whistler Project consists of several gold-copper porphyry deposits and exploration targets, with a mineral resource estimate of 294 million tonnes at 0.68 g/t AuEq for 6.48 million ounces AuEq indicated, and 198 million tonnes at 0.65 g/t AuEq for 4.16 million ounces AuEq inferred [11].

Core Viewpoint - Ocular Therapeutix, Inc. is actively participating in several investor and scientific conferences in September 2025 to showcase its advancements in retinal therapies and engage with the investment community [1][2][3]. Upcoming Investor Conferences - Ocular Therapeutix will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, from 2:35 to 3:10 PM ET, with Dr. Pravin U. Dugel as the presenter [2]. - The company will also participate in the Baird 2025 Global Healthcare Conference on September 9, 2025, from 12:50 to 1:20 PM ET, again featuring Dr. Pravin U. Dugel [2]. - Live webcasts of these presentations will be available on the Ocular Therapeutix website, with replays archived for at least 30 days [2]. Upcoming Scientific Conferences - Ocular Therapeutix will present at the EURETINA Innovation Spotlight on September 3, 2025, in Paris, focusing on redefining the retina experience, with Dr. Peter K. Kaiser as the presenter [3]. - The company will also participate in the Ophthalmology Futures Forums Retina Forum on the same day, with Dr. Peter K. Kaiser presenting in two sessions [4][5]. - At the 25th EURETINA Congress from September 4-7, 2025, Ocular will host a symposium titled "Advancing Retinal Disease Treatment: Exploring OTX-TKI's Potential to Extend Treatment Durability" on September 6, 2025 [5]. Company Overview - Ocular Therapeutix is an integrated biopharmaceutical company focused on redefining the retina experience, with its investigational product AXPAXLI™ (OTX-TKI) currently in Phase 3 clinical trials for wet age-related macular degeneration [8]. - The company also leverages its proprietary ELUTYX™ technology in its commercial product DEXTENZA, an FDA-approved corticosteroid for treating ocular inflammation and pain, and in its investigational product OTX-TIC, currently in Phase 2 trials for open-angle glaucoma [9].

Not for distribution to United States newswire services or for release publication, distribution or dissemination, directly or indirectly, in whole or in part, in or into the United States. TORONTO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Voyageur Mineral Explorers Corp. (CSE: VOY) (“Voyageur” or the “Company”) and Evolve Strategic Element Royalties Inc. (“Evolve”) are pleased to announce that the parties have entered into a definitive business combination agreement dated August 26, 2025 (the “Definitive Agreemen ...

"In parallel with the wave rollout, VA is able to take advantage of new capabilities and help drive the roadmap and design of those capabilities as part of the supported COTS solution," said Monica Winthrop, Senior Vice- President Consulting Services of Veterans Affairs, CGI. "CGI invests in the Momentum Enterprise Suite, incorporating features recommended by the extensive user community across all three branches of the government." CGI's Momentum® Enterprise Suite leverages the full potential of integrated ...

Company Overview - Reliance, Inc. is a leading global diversified metal solutions provider and the largest metals service center company in North America, founded in 1939 [3] - The company operates approximately 320 locations across 41 states and 10 countries outside the United States, serving over 125,000 customers in various industries [3] - Reliance offers a full line of over 100,000 metal products and focuses on small orders with quick turnaround and value-added processing services [3] Financial and Operational Highlights - In 2024, Reliance's average order size was $2,980, with approximately 50% of orders including value-added processing [3] - Approximately 40% of orders were delivered within 24 hours, indicating a strong operational efficiency [3] Upcoming Events - Karla Lewis, President and CEO, and Stephen Koch, Executive Vice President and COO, will participate in the Jefferies Industrials Conference on September 3, 2025, at 3:30 p.m. ET [1] - The presentation will be webcast live and available for replay on the company's website for 90 days following the event [2]

Core Insights - Brazil Potash Corp. has been invited by the Mura Indigenous Council to participate in the FECIM Festival, highlighting the strengthening partnership with the Mura Indigenous communities [1][2][3] - The festival is set to take place on August 29 and 30, 2025, at Jair Tupinambá Park in Autazes, with additional invitations for community events and a lunch in the village [2] - The invitations follow a Preliminary Cooperation Agreement signed in January 2025, aimed at establishing a "Mura Well Being" sustainable development program [3] Company Overview - Brazil Potash is developing the Autazes Potash Project to supply sustainable fertilizers, addressing Brazil's reliance on potash imports, which exceeded 95% in 2021 [5] - The project is expected to produce up to 2.4 million tons of potash annually, potentially meeting approximately 20% of Brazil's current potash demand [5] - The company plans to transport potash using low-cost river barges in partnership with Amaggi, a major agricultural operator in Brazil [5] - The initiative aims to reduce greenhouse gas emissions by approximately 1.4 million tons per year while supporting Brazil's food security [5][3] Community Engagement - The Mura Indigenous Council represents over 18,000 Mura Indigenous people and plays a crucial role as stakeholders in the Autazes Potash Project [4] - The participation in the FECIM Festival signifies the company's commitment to cultural respect and sustainable development in collaboration with local communities [3][2]